首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1241篇
  免费   145篇
  国内免费   25篇
耳鼻咽喉   11篇
儿科学   7篇
妇产科学   25篇
基础医学   101篇
口腔科学   33篇
临床医学   150篇
内科学   175篇
皮肤病学   7篇
神经病学   92篇
特种医学   61篇
外科学   135篇
综合类   185篇
预防医学   82篇
眼科学   19篇
药学   170篇
  2篇
中国医学   43篇
肿瘤学   113篇
  2024年   12篇
  2023年   115篇
  2022年   108篇
  2021年   95篇
  2020年   108篇
  2019年   47篇
  2018年   42篇
  2017年   35篇
  2016年   32篇
  2015年   48篇
  2014年   80篇
  2013年   60篇
  2012年   70篇
  2011年   86篇
  2010年   89篇
  2009年   54篇
  2008年   56篇
  2007年   38篇
  2006年   32篇
  2005年   27篇
  2004年   25篇
  2003年   18篇
  2002年   19篇
  2001年   23篇
  2000年   21篇
  1999年   15篇
  1998年   17篇
  1997年   10篇
  1996年   3篇
  1995年   5篇
  1994年   1篇
  1993年   2篇
  1992年   1篇
  1991年   1篇
  1990年   3篇
  1989年   3篇
  1988年   3篇
  1987年   3篇
  1986年   3篇
  1985年   1篇
排序方式: 共有1411条查询结果,搜索用时 275 毫秒
1.
2.
3.
This study aimed to observe the therapeutic effects of magnesium lithospermate B on acute and chronic colitis induced by dextran sodiumsulfate (DSS) and the role of inflammasome complex (NOD-like receptor protein, NLRP; apoptosis-associated speck-like protein containing, ASC; caspase-1). Establishment of acute and chronic colitis models were by using 5% DSS oral administration in BALB/C male mice. Magnesium lithospermate B (240 mg/kg body weight) was given by subcutaneous injection. Samples were collected for biomarker assay, histological examination, immunohistochemical evaluation and western blot. There was obvious increase in TNF-α level and NLPR3, ASC, and caspase-1 expressions in acute and chronic colitis groups compared with the normal control. Significant decrease of the tumor necrosis factor-α level and the expressions of NLPR3, ASC, and caspase-1 were observed after treatment with magnesium lithospermate B. This study showed that magnesium lithospermate B could be used to treat acute and chronic colitis by inhibiting the activation of the NLRP3/ASC/Caspase-1 pathway.  相似文献   
4.
《Injury》2021,52(4):705-712
Intramedullary nails are the common treatment options for femoral intertrochanteric fractures. However, aseptic loosening is considered to be one of the primary forms of failure that can be caused by the stress shielding between the bone and implants. The matching in mechanical properties of implant and bone is a key issue to prevent this failure. Polyetheretherketone (PEEK) and Function-graded (FG) materials are widely used in clinical because of their excellent mechanical properties. In this study, to investigate the biomechanical behaviors of intramedullary nails made of Ti-6Al-4V alloy, Stainless Steel (SS), PEEK and two FG materials, three-dimensional finite element models of intertrochanteric fracture femur with intramedullary nail were constructed with ABAQUS. The maximum von Mises stress on the femoral fracture surface fixed by PEEK intramedullary nail was the largest, followed by FG intramedullary nail, which help stimulate bone growth and subsequently reduce fracture healing time. Compared with traditional metal intramedullary nails, PEEK and FG implants might increase von Mises stress along the same path in the proximal femur. The results showed that PEEK and FG intramedullary nails obviously changed the stress distributions in the bone and reduced stress shielding. This finding indicated that PEEK and FG intramedullary nails have the potential to become alternatives to the conventional metal intramedullary nails.  相似文献   
5.
目的 探讨γ干扰素诱导蛋白30(IFI 30)、程序性死亡因子配体1(PD-L1)在人脑胶质瘤中的表达及与病人预后的关系。方法 选择2015年5月~2019年5月手术切除的103例人脑胶质瘤组织和瘤旁组织,采用免疫组织化学染色检测IFI 30、PD-L1表达情况。随访24个月,记录无进展生存期和总生存期。结果 胶质瘤组织IFI 30、PD-L1高表达率[分别为70.87%(73/103)、68.93%(71/103)]明显高于瘤旁组织[分别为19.42%(20/103)、21.36%(22/103);P<0.001]。胶质瘤组织IFI 30表达水平与PD-L1表达水平呈明显正相关(r=0.583,P<0.05)。随访24个月,生存75例,死亡28例;多因素logistic回归分析显示,IFI 30高表达、PD-L1高表达是增加病人死亡风险的独立危险因素(P<0.05)。生存曲线分析显示,IFI 30高表达组2年累积生存率(64.52%)和2年累积无进展生存率(65.56%)均明显低于低表达组(分别为82.25%、89.45%;P<0.05)。PD-L1高表达组2年累积生存率(61.78%)和2年累积无进展生存率(60.14%)均明显低于低表达组(分别为88.52%、79.86%;P<0.05)。结论 人脑胶质瘤组织IFI 30、PD-L1呈高表达,与病人不良预后密切相关。  相似文献   
6.
7.
8.
肝脏少见恶性肿瘤的CT表现   总被引:9,自引:3,他引:6  
目的 分析5例不同组织类型的肝脏少见恶性肿瘤的CT表现,以提高对这些恶性肿瘤的识别能力。方法 经临床和病理证实的肝脏少见恶性肿瘤5例,均行CT检查,其中肝肉瘤3例(包括血管肉瘤1例,恶性间叶瘤1例,恶性纤维组织细胞瘤1例,类癌2例)。结果 上述肝脏恶性肿瘤表现多样化,恶性间叶瘤以儿童肝内巨大单发囊性为主病灶;肝血管肉瘤表现为肝内多发境界清楚的低密度灶,可合并坏死、囊变及新鲜出血,无肝硬化基础;恶性纤维组织细胞瘤为肝右叶单发巨块低密度病灶,可伴纤维分隔,免疫组织化学标记具有诊断价值;类癌CT特征为肝内单发或多发病灶,密度不均匀,呈单房或多房,增强表现实质部分强化,伴类癌综合征时更具有诊断价值。结论 本组分析的5例肝脏恶性肿瘤临床均较少见,各种病理类型的此类肿瘤有其相似和不同的CT征象,结合临床及实验室检查,应在临床诊断中考虑到上述肿瘤的可能,以免漏诊或误诊。  相似文献   
9.
肾上腺脑白质营养不良MRI表现(附3例报告及文献复习)   总被引:1,自引:0,他引:1  
目的 探讨肾上腺脑白质营养不良的MRI特征,提高对本病的认识。方法 回顾性分析3例经临床和生化证实的。肾上腺脑白质营养不良患者的MRI表现。结果 3例患者均表现为双侧对称性侧脑室三角区白质病变,T1WI呈低信号,T2WI呈高信号,经胼胝体压部相连,呈蝶翼状分布。结论肾上腺脑白质营养不良的MRI表现具有典型特征,MR检查能准确反映病变的病理变化、范围及进展情况。MRI作为一种无创性并且敏感的检查方法,在对肾上腺脑白质营养不良的诊断和治疗方面具有重要的指导意义。  相似文献   
10.

Background/Purpose

Nemonoxacin is a novel nonfluorinated quinolone with excellent in vitro activity against most pathogens in community-acquired pneumonia (CAP), especially Gram-positive isolates. The purpose of this study was to assess the efficacy and safety of nemonoxacin compared with levofloxacin in patients with CAP.

Methods

A phase 3, multicenter, randomized (2:1) controlled trial was conducted in adult CAP patients receiving nemonoxacin 500 mg or levofloxacin 500 mg orally once daily for 7–10 days. Clinical, microbiological response and adverse events were assessed. Non-inferiority was determined in terms of clinical cure rate of nemonoxacin compared with that of levofloxacin in a modified intention-to-treat (mITT) population. NCT registration number: NCT01529476.

Results

A total of 527 patients were randomized and treated with nemonoxacin (n = 356) or levofloxacin (n = 171). The clinical cure rate at test-of-cure visit was 94.3% (300/318) for nemonoxacin and 93.5% (143/153) for levofloxacin in the mITT population [difference (95% CI), 0.9% (?3.8%, 5.5%)]. The microbiological success rate was 92.1% (105/114) for nemonoxacin and 91.7% (55/60) for levofloxacin in the bacteriological mITT population [difference (95% CI), 0.4% (?8.1%, 9.0%)]. The incidence of adverse events (AEs) was comparable between nemonoxacin (33.1%, 118/356) and levofloxacin (33.3%, 57/171) (P > 0.05).

Conclusion

Nemonoxacin 500 mg once daily for 7–10 days is as effective and safe as levofloxacin for treating adult CAP patients in terms of clinical cure rates, microbiological success rates, and safety profile.ClinicalTrials.gov identifier: NCT01529476.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号